Señales en vivo de ABVX.PA | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 11:35):

Stats
Volumen de hoy	13 478.00
Volumen promedio	30 185.00
Capitalización de mercado	932.44M
EPS	€0 ( 2024-04-07 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-4.32
ATR14	€0.0470 (0.32%)

Volumen Correlación

Largo: -0.05 (neutral)

Corto: 0.77 (moderate)

Signal:(59.777) Neutral

Abivax SA Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Abivax SA Correlación - Moneda/Commodity

-0.16
( neutral )

-0.25
( neutral )

0.00
( neutral )

0.01
( neutral )

0.09
( neutral )

-0.16
( neutral )

Abivax SA Finanzas

Annual	2023
Ingresos:	€4.62M
Beneficio Bruto:	€3.91M (84.70 %)
EPS:	€-3.43

FY	2023
Ingresos:	€4.62M
Beneficio Bruto:	€3.91M (84.70 %)
EPS:	€-3.43

FY	2022
Ingresos:	€0
Beneficio Bruto:	€-71 000.00 (0.00 %)
EPS:	€-3.13

FY	2021
Ingresos:	€37 000.00
Beneficio Bruto:	€37 000.00 (100.00 %)
EPS:	€-3.39

Financial Reports:

No articles found.

Abivax SA

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.